Electrical Components and Equipment

NUODE

NUODE released FY2025 annual earnings on April 22 After-Market (BJT), actual revenue CNY 7.328 B (forecast CNY 7.391 B), actual EPS CNY -0.1734 (forecast CNY -0.1462)

NUODE released FY2026 Q1 earnings on April 22 After-Market (BJT), actual revenue CNY 2.543 B (forecast CNY 2.563 B), actual EPS CNY 0.0233 (forecast CNY 0.0261)

NUODE released FY2025 Q4 earnings on April 22 After-Market (BJT), actual revenue CNY 2.535 B (forecast CNY 2.599 B), actual EPS CNY -0.1192 (forecast CNY -0.0923)

NUODE to Release FY2026 Q1 Earnings on April 23 After-Market (BJT), Forecast Revenue CNY 2.563 B, EPS CNY 0.0261

NUODE to Release FY2025 Earnings on April 23 After-Market (BJT), Forecast Revenue CNY 7.391 B, EPS CNY -0.1462

NUODE released FY2025 Q3 earnings on October 22 Pre-Market (BJT), actual revenue CNY 1.777 B (forecast CNY 1.747 B), actual EPS CNY -0.0123 (forecast CNY -0.0041)

NUODE released FY2025 9 Months Earnings on October 22 Pre-Market (BJT), actual revenue CNY 4.793 B, actual EPS CNY -0.0544

NUODE to Release FY2025 Q3 Earnings on October 23 Pre-Market (BJT), Forecast Revenue CNY 1.747 B, EPS CNY -0.0041

NUODE released FY2025 Q2 earnings on August 29 After-Market BJT, actual revenue CNY 1.606 B (forecast CNY 1.735 B), actual EPS CNY -0.0202 (forecast CNY -0.0196)

NUODE released FY2025 Semi-Annual Earnings on August 29 After-Market (BJT), Actual Revenue: CNY 3.016 B, Actual EPS: CNY -0.0421

NUODE FY2025 Semi-Annual Earnings Release on August 30, 2025 (BJT)

Nord Photovoltaic Technology Co., Ltd Established

Nord Photonics Energy Management Co., Ltd. Established

Nod Co. Forecasts A Net Loss of 70 Million in First Half of 2025

Nord 股份 plans to sell 70% equity of Jiangsu Lianxin

Nord Shares ESG Rating Remains at B Level

Nord Shares Plunge After Responding to Annual Report Inquiry

Nord Shares Abnormal Fluctuations and Solid State Battery Business Explanation

Nord Shares Issued Stock Trading Risk Warning

Nord Stocks Issues Risk Warning on Solid State Battery Business

688345

688388

300438

600110

600241

002245

301511

Lithium battery sector fluctuates and strengthens, NUODE and Jiangsu Azure Corporation hit the daily limit, Greenway rises over 10%, Great Power, Guangdong Jiayuan Technology, Defu Technology, and SDWH rise over 5%

Wallstreetcn

Greenway

Guangdong Jiayuan Technology

Great Power

SDWH

Jiangsu Azure Corporation

Defu Technology

March 26 (Reuters) - The U.S. Food and Drug Administration (FDA) has approved Novo Nordisk's insulin injection, Awiqli, to improve blood sugar levels in adults living with type 2 diabetes, the company said on Thursday. (Reporting by Carlos Méndez in Mexico City; Editing by Rashmi Aich)

Fidelity

First Trust NYSE Arca Biotech Index Fd

Novo Nordisk AS

US FDA approves Novo's insulin injection for type 2 diabetes

Indian pharmaceutical companies are preparing to launch generic versions of semaglutide, following the expiration of Novo Nordisk's patent. Major firms like Cipla and Sun Pharma are expected to reduce prices by 50-70%. With rising obesity and diabetes rates in India, the market for these drugs is projected to grow significantly, from $16 million in 2021 to $100 million by 2025. However, concerns about drug quality and safety persist, especially given past scandals and the risk of counterfeiting. Proper medical supervision is crucial for effective use of these weight-loss drugs.

Business Standard

Effective oversight: Safety crucial for success of weight-loss drugs

516930

Novo Nordisk: Wegovy HD (Semaglutide 7.2 mg) has been approved in the United States. The drug has been shown to achieve a weight loss of 20.7%

Minsheng Royal CSI Biotechnology Theme ETF

Novo Nordisk AS received a warning letter from the FDA for failing to report all suspected side effects of the weight loss drug Ozempic. The letter mentioned two cases of death and one case of suicide, with patients all receiving treatment with semaglutide. The FDA did not explicitly state whether these events were related to the drug. The stock recently fell by 3%

AASTOCKS

The FDA warns that Novo Nordisk has not reported side effects or death cases related to the weight loss drug Ozempic

159992

516820

512010

513120

159615

588130

512290

588860

Novo Nordisk's authorized drug UBT251 shows impressive Phase II clinical data in China: a maximum weight loss of 19.7% after 24 weeks of treatment (only 2% for the placebo), and the company stated it is "very encouraged." However, affected by negative news regarding Cagrisema, the stock price still fell over 4%. Novo Nordisk has paid a $200 million upfront payment, with the total deal potentially reaching $2 billion, aimed at finding new growth points in the weight loss drug market

- Novo Nordisk's experimental weight loss drug UBT251 showed significant weight reduction in a Phase II clinical trial in China, supporting the company's growth in the competitive weight loss market.  
- After 24 weeks of treatment, patients lost up to 19.7% of their weight, compared to only 2% for those on a placebo.  
- Despite promising trial results, Novo Nordisk's stock has suffered, dropping over 60% in the past year due to market pressures and negative news related to its next-generation weight loss drug, Cagrisema.

Yinhua CSI Innovative Drugs Industry ETF

Ping An CSI Medicine and Medical Device Innovation ETF

E Fund CSI 300 Health Care ETF

E Fund Hang Seng SCHK Innovative Drug ETF

Tianhong CNI BIOMEDICINE ETF

ChinaAMC CSI Biotechnology Theme ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

E Fund CSI Biotechnology Theme ETF

Huaan Hang Seng Biotech ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

ChinaAMC SSE Health Care ETF Initiating Fund

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

China Southern Hang Seng Biotech ETF(QDII)

ChinaAMC SSE STAR Biology and Medicine ETF

Guotai CSI Bio-medicine ETF

Bosera Hang Seng Health Care ETF(QDII)

ICBCCS SSE STAR Biology and Medicine ETF

China Merchants CSI Biotechnology Theme ETF

Penghua SSE STAR Biology and Medicine ETF

Novo Nordisk UBT251 shows impressive phase II clinical data in China, with a weight loss effect of nearly 20%